Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 34INDUSTRY 11NIH 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Ovarian Neoplasms 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Colorectal Neoplasms 7Prostatic Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Lymphoma 5Head and Neck Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Neoplasms 4Leukemia, Myeloid, Acute 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Stomach Neoplasms 3Sezary Syndrome 3Salivary Gland Neoplasms 3Rhabdoid Tumor 3Rectal Neoplasms 3Pain 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Melanoma 3Lymphoma, T-Cell, Cutaneous 3

Interventions

olaparib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Triple Negative Breast Neoplasms × Clear all
NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡